Patent Issued for Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use (USPTO 12030952).

A patent has been issued for bispecific anti-human CD20/human transferrin receptor antibodies and methods of use. The patent describes the use of these antibodies to target CD20, a protein found on B-cells, in the treatment of B-cell lymphomas and autoimmune diseases. The antibodies can be administered to patients to destroy neoplastic B-cells or relieve symptoms of autoimmune disorders. The patent also includes claims for the composition of the antibodies and methods of treating multiple sclerosis. The assignee for the patent is F. Hoffmann-La Roche Inc. [Extracted from the article]